Investors might want to bet on Pieris Pharmaceuticals (PIRS), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Pieris received a grant of $17 million from the Bavarian Ministry of Economic Affairs for a drug to treat lung scarring in COVID sufferers. Shares of Pieris Pharmaceuticals (PIRS) jumped on Friday ...

Pieris Pharmaceuticals’ PIRS shares were up almost 12% on Jul 18, after management announced strategic update in light of the recent events that have impacted its respiratory franchise. In order to ...

AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals’ asthma med, forcing the biotech to begin charting a new corporate course and lay off 70% of its staff in the process. The ...

Pieris Pharmaceuticals Inc PIRS announced that partner AstraZeneca plc AZN decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4 receptor alpha ...

Pursuant to the terms and conditions of the License Agreement, Pieris is licensing from Enumeral specified intellectual property related to Enumeral’s anti-PD-1 antibody program ENUM 388D4 for the ...

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strategic options”. AZ bought into ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Pieris Pharmaceuticals ( (PIRS)) has ...

Investors might want to bet on Pieris Pharmaceuticals (PIRS), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...